Abstract | BACKGROUND:
Telavancin is approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) based on the results of the Phase 3 Assessment of TeLAvancin in complicated Skin and skin structure infections (ATLAS) trials, which demonstrated non-inferiority of telavancin to vancomycin. METHODS: We conducted a post hoc analysis of the ATLAS studies (ClinicalTrials.gov identifiers NCT00091819 and NCT00107978) to explore the efficacy of telavancin in patients with various types of cSSSIs. RESULTS: A total of 1794 patients were included in this analysis; 1434 patients were clinically evaluable (CE) and 563 of these had methicillin-resistant Staphylococcus aureus (MRSA). Among CE patients with major abscesses (n = 619), cure rates were 91% for telavancin and 90% for vancomycin (95% CI for the difference -3.6 to 5.7). In patients with infective cellulitis (n = 519), cure was achieved in 87% and 88% of telavancin- and vancomycin-treated patients, respectively (95% CI for the difference -6.2 to 5.2). Cure rates in patients with wound infections were 85% in the telavancin group and 86% in the vancomycin group (95% CI for the difference -10.5 to 9.0). Cure rates for each type of cSSSI in patients infected with MRSA were also similar between the two treatment arms. Among CE patients infected with Panton-Valentine leucocidin (PVL)-positive MRSA (n = 447), cure rates were 93% for telavancin and 90% for vancomycin (95% CI for the difference -2.2 to 8.2). CONCLUSIONS: Cure rates were similar for telavancin and vancomycin in patients with different types of cSSSIs, including infections caused by MRSA and PVL-positive strains of MRSA.
|
Authors | Martin E Stryjewski, Steven L Barriere, William O'Riordan, Lala M Dunbar, Alan Hopkins, Fredric C Genter, G Ralph Corey |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 67
Issue 6
Pg. 1496-502
(Jun 2012)
ISSN: 1460-2091 [Electronic] England |
PMID | 22416054
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aminoglycosides
- Anti-Bacterial Agents
- Bacterial Toxins
- Exotoxins
- Leukocidins
- Lipoglycopeptides
- Panton-Valentine leukocidin
- Virulence Factors
- telavancin
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Aminoglycosides
(therapeutic use)
- Anti-Bacterial Agents
(therapeutic use)
- Bacterial Toxins
(genetics)
- Exotoxins
(genetics)
- Female
- Humans
- Leukocidins
(genetics)
- Lipoglycopeptides
- Male
- Methicillin-Resistant Staphylococcus aureus
(drug effects, isolation & purification)
- Middle Aged
- Randomized Controlled Trials as Topic
- Staphylococcal Skin Infections
(drug therapy)
- Treatment Outcome
- United States
- Virulence Factors
(genetics)
- Young Adult
|